BR112015030490A2 - (+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesma - Google Patents
(+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesmaInfo
- Publication number
- BR112015030490A2 BR112015030490A2 BR112015030490A BR112015030490A BR112015030490A2 BR 112015030490 A2 BR112015030490 A2 BR 112015030490A2 BR 112015030490 A BR112015030490 A BR 112015030490A BR 112015030490 A BR112015030490 A BR 112015030490A BR 112015030490 A2 BR112015030490 A2 BR 112015030490A2
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- imidazolidine
- dione
- oxopyridin
- difluorophenyl
- Prior art date
Links
- HEHGUDVOXPGLAU-UHFFFAOYSA-N 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1-yl)methyl]imidazolidine-2,4-dione Chemical compound O=C1C(C)=CC=CN1CC1(C=2C=C(F)C(F)=CC=2)C(=O)NC(=O)N1 HEHGUDVOXPGLAU-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 3-methyl-2-oxopyridin-1(2h)-yl Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quick-Acting Or Multi-Walled Pipe Joints (AREA)
Abstract
1/1 resumo (+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil] imidazolidino-2,4-diona e medicamento contendo a mesma a presente invenção refere-se a (+)-5-(3,4-difluorofenil)-5-[(3-metil-2oxopiridin- 1(2h)-il)metil]imidazolidino-2,4-diona ou um sal da mesma. também é fornecido um medicamento contendo como o ingrediente ativo a (+)-5-(3,4difluorofenil)- 5-[(3-metil-2-oxopiridin-1(2h)-il)metil]imidazolidino-2,4-diona ou um sal da mesma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013120692 | 2013-06-07 | ||
JP2013-120692 | 2013-06-07 | ||
PCT/JP2014/065060 WO2014196623A1 (ja) | 2013-06-07 | 2014-06-06 | (+)-5-(3,4-ジフルオロフェニル)-5-[(3-メチル-2-オキソピリジン-1(2h)-イル)メチル]イミダゾリジン-2,4-ジオンおよびそれを含有する医薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015030490A2 true BR112015030490A2 (pt) | 2017-07-25 |
BR112015030490B1 BR112015030490B1 (pt) | 2022-01-18 |
Family
ID=52008252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015030490-7A BR112015030490B1 (pt) | 2013-06-07 | 2014-06-06 | (+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesma |
Country Status (19)
Country | Link |
---|---|
US (1) | US9518041B2 (pt) |
EP (1) | EP3006437B1 (pt) |
JP (1) | JP6247689B2 (pt) |
KR (2) | KR102321814B1 (pt) |
CN (1) | CN105531270B (pt) |
AU (1) | AU2014275835B2 (pt) |
BR (1) | BR112015030490B1 (pt) |
CA (1) | CA2913858C (pt) |
ES (1) | ES2818931T3 (pt) |
HK (1) | HK1221219A1 (pt) |
IL (1) | IL242861B (pt) |
MX (1) | MX364780B (pt) |
MY (1) | MY173075A (pt) |
NZ (1) | NZ714700A (pt) |
PH (1) | PH12015502661B1 (pt) |
RU (1) | RU2668072C2 (pt) |
SG (1) | SG11201509835RA (pt) |
TW (1) | TWI636782B (pt) |
WO (1) | WO2014196623A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160168540A1 (en) * | 2013-06-07 | 2016-06-16 | Kaken Pharmaceutical Co., Ltd. | Composition for maintaining platelet function |
CN107304205B (zh) * | 2016-04-22 | 2020-10-30 | 上海医药工业研究院 | 一种马拉韦罗中间体及其制备方法 |
WO2018056373A1 (ja) | 2016-09-23 | 2018-03-29 | 科研製薬株式会社 | (r)‐5‐(3,4‐ジフルオロフェニル)‐5‐[(3‐メチル‐2‐オキソピリジン‐1(2h)‐イル)メチル]イミダゾリジン‐2,4‐ジオンの製造方法およびその製造のための中間体 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE200300439A (et) * | 2001-03-15 | 2003-12-15 | Astrazeneca Ab | Metalloproteinaasi inhibiitorid |
ES2319970T3 (es) | 2001-09-07 | 2009-05-18 | Kaken Pharmaceutical Co., Ltd. | Derivados de acido hidroxamico inverso. |
GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US7041693B2 (en) | 2002-10-04 | 2006-05-09 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
US7132432B2 (en) | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
ATE478864T1 (de) | 2004-07-16 | 2010-09-15 | Schering Corp | Hydantoinderivate zur behandlung von entzündlichen erkrankungen |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
PE20071241A1 (es) | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
US20110082133A1 (en) * | 2008-06-17 | 2011-04-07 | Takashi Kamikubo | Pyridone compounds |
AR073741A1 (es) | 2008-09-24 | 2010-12-01 | Schering Corp | Derivados heterociclicos de hidantoina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias, tales como psoriasis o artritis |
WO2010054278A2 (en) | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
JP6091427B2 (ja) * | 2011-12-09 | 2017-03-08 | 科研製薬株式会社 | ピリドン誘導体およびそれを含有する医薬 |
-
2014
- 2014-06-06 MX MX2015016828A patent/MX364780B/es active IP Right Grant
- 2014-06-06 BR BR112015030490-7A patent/BR112015030490B1/pt active IP Right Grant
- 2014-06-06 AU AU2014275835A patent/AU2014275835B2/en active Active
- 2014-06-06 RU RU2015156531A patent/RU2668072C2/ru active
- 2014-06-06 JP JP2015521499A patent/JP6247689B2/ja active Active
- 2014-06-06 MY MYPI2015704380A patent/MY173075A/en unknown
- 2014-06-06 KR KR1020157034539A patent/KR102321814B1/ko active IP Right Grant
- 2014-06-06 CN CN201480032095.3A patent/CN105531270B/zh active Active
- 2014-06-06 WO PCT/JP2014/065060 patent/WO2014196623A1/ja active Application Filing
- 2014-06-06 EP EP14806840.6A patent/EP3006437B1/en active Active
- 2014-06-06 ES ES14806840T patent/ES2818931T3/es active Active
- 2014-06-06 SG SG11201509835RA patent/SG11201509835RA/en unknown
- 2014-06-06 TW TW103119743A patent/TWI636782B/zh active
- 2014-06-06 KR KR1020217035383A patent/KR102379801B1/ko active IP Right Grant
- 2014-06-06 US US14/895,768 patent/US9518041B2/en active Active
- 2014-06-06 CA CA2913858A patent/CA2913858C/en active Active
- 2014-06-06 NZ NZ714700A patent/NZ714700A/en unknown
-
2015
- 2015-11-27 PH PH12015502661A patent/PH12015502661B1/en unknown
- 2015-11-30 IL IL242861A patent/IL242861B/en active IP Right Grant
-
2016
- 2016-08-04 HK HK16109328.6A patent/HK1221219A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
NZ745556A (en) | Androgen receptor modulator and uses thereof | |
DK201470535A (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
PH12016500356A1 (en) | Nsaid and sigma receptor ligand combinations | |
BR112013008005A2 (pt) | composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo | |
TR201904614T4 (tr) | Novel pyrazole derivative. | |
BR112015016930A2 (pt) | formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina | |
PH12015502282A1 (en) | Alpha-2 adrenoceptor and sigma receptor ligand combinations | |
PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
BR112015008459A2 (pt) | método veterinário de aliviar a aversão ao ruído | |
BR112015026967A8 (pt) | fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica | |
BR112012028047A2 (pt) | sistema de cateter, cateter, método de administração de um agente a um paciente e método para variar uma dosagem de um agente ativo | |
BR112015030490A2 (pt) | (+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesma | |
BR112019018028A2 (pt) | Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
BR112015010823A2 (pt) | composto de 2-piridona | |
CL2016000013A1 (es) | Nueva sal de la 3-[(3-([4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen)-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su procedimiento de preparación y las formulaciones que la contienen. | |
UA109944U (uk) | Фармацевтична композиція для зниження рівня n-оксиду триметиламіну | |
BR112016008704A8 (pt) | derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos | |
EA201690762A1 (ru) | {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек | |
BR112015022000A2 (pt) | drogas de combinações farmacêuticas | |
PL401992A1 (pl) | 2-benzoiloamino-5-(izochinolin-3-ylo)-1,3,4-tiadiazol, sposób jego wytwarzania oraz zastosowanie medyczne | |
PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną | |
PL399880A1 (pl) | 8-(oktadecylosulfanylo)chinolina do zastosowania jako lek, zwlaszcza do stosowania w leczeniu i profilaktyce rozwoju insulinoopornosci, kompozycja farmaceutyczna zawierajaca 8-(oktadecylosulfanylo)chinoline oraz zastosowanie 8-(oktadecylosulfanylo)chinoliny do wytwarzania leku do stosowania w leczeniu i profilaktyce rozwoju insulinoopornosci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2014, OBSERVADAS AS CONDICOES LEGAIS. |